 |
|
Prenatal Magnesium Sulfate Exposure and the Risk for Cerebral Palsy or Mental Retardation Among Very Low-Birth-Weight Children Aged 3 to 5 Years
Diana E. Schendel, PhD;
Cynthia J. Berg, MD;
Marshalyn Yeargin-Allsopp, MD;
Coleen A. Boyle, PhD;
Pierre Decoufle, ScD
JAMA. 1996;276(22):1805-1810.
Abstract
| |
Objective.
—To examine the relationship between prenatal magnesium sulfate exposure and the risk for cerebral palsy (CP) or mental retardation (MR) among very low-birth-weight (VLBW; <1500 g) children. Secondarily, to investigate the effect of prenatal magnesium sulfate exposure on VLBW infant mortality.
Design.
—Cohort study with follow-up to 1 year of age; a subset followed up to 3 to 5 years.
Setting.
—Twenty-nine Georgia counties, including the 5-county Atlanta metropolitan area.
Participants.
—All VLBW births (N=1097) occurring during 2 years (1986-1988); all metropolitan Atlanta VLBW neonates who survived infancy (N=519).
Main Outcome Measures.
—Infant mortality as determined from vital statistics records. Development of CP or MR by 3 to 5 years of age among metropolitan Atlanta VLBW survivors as determined from the Metropolitan Atlanta Developmental Disabilities Surveillance Program.
Results.
—For the entire cohort, there was no association between prenatal magnesium sulfate exposure and infant mortality (adjusted rate ratio, 1.02; 95% confidence interval [CI], 0.83-1.25). Among Atlanta-born survivors, those exposed to magnesium sulfate had a lower prevalence of CP or MR than those not exposed (CP: magnesium sulfate, 0.9%, no magnesium sulfate, 7.7%, crude odds ratio [OR], 0.11, 95% CI, 0.02-0.81; MR: magnesium sulfate, 1.8%, no magnesium sulfate, 5.8%, crude OR, 0.30,95% CI, 0.07-1.29). Multivariable adjustment had no appreciable effect on the ORs for CP or MR, but the CIs included 1.0.
Conclusions.
—A reduced risk for CP, and possibly MR, among VLBW children is associated with prenatal magnesium sulfate exposure. The reduced risk for childhood CP or MR does not appear to be due to selective mortality of magnesium sulfate—exposed infants.
Author Affiliations
From the Developmental Disabilities Branch, Division of Birth Defects and Developmental Disabilities, National Center for Environmental Health (Drs Schendel, Yeargin-Allsopp, Boyle, and Decoufle), and the Pregnancy and Infant Health Branch, Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion (Dr Berg), Centers for Disease Control and Prevention, Atlanta, Ga.
Footnotes
Reprints: Diana E. Schendel, PhD, Developmental Disabilities Branch, Division of Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, 4770 Buford Hwy NE, Mailstop F15, Chamblee, GA 30341-3724 (e-mail: dcs6@cehbddd. em.cdc.gov).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Magnesium Sulfate in Severe Perinatal Asphyxia: A Randomized, Placebo-Controlled Trial
Bhat et al.
Pediatrics 2009;123:e764-e769.
ABSTRACT
| FULL TEXT
Effect of Magnesium Sulfate Given for Neuroprotection Before Preterm Birth: A Randomized Controlled Trial
Crowther et al.
JAMA 2003;290:2669-2676.
ABSTRACT
| FULL TEXT
Hope for Perinatal Prevention of Cerebral Palsy
Tyson and Gilstrap
JAMA 2003;290:2730-2732.
FULL TEXT
Perinatal Brain Damage: Underlying Mechanisms and Neuroprotective Strategies
Berger et al.
Reproductive Sciences 2002;9:319-328.
ABSTRACT
Effect of Long-Term, Postasphyxial Administration of Magnesium Sulfate on Immunostaining of Microtubule-Associated Protein-2 and Activated Caspase-3 in 7-Day-Old Rat Brain
Sameshima and Ikenoue
Reproductive Sciences 2002;9:203-209.
ABSTRACT
Neuroprotective Effects of Magnesium on Metabolic Disturbance in Fetal Hippocampal Slices After Oxygen-Glucose Deprivation: Mediation By Nitric Oxide System
Garnier et al.
Reproductive Sciences 2002;9:86-92.
ABSTRACT
Tocolytic Magnesium Sulfate Exposure and Risk of Cerebral Palsy among Children with Birth Weights Less Than 1,750 Grams
Boyle et al.
Am J Epidemiol 2000;152:120-124.
ABSTRACT
| FULL TEXT
Placental delivery of arachidonic and docosahexaenoic acids: implications for the lipid nutrition of preterm infants
Crawford
Am. J. Clin. Nutr. 2000;71:275S-284S.
ABSTRACT
| FULL TEXT
The Control of Labor
Pryde et al.
NEJM 1999;341:2098-2099.
FULL TEXT
Maternal hypertension and neurodevelopmental outcome in very preterm infants
Gray et al.
Arch. Dis. Child. Fetal Neonatal Ed. 1998;79:88F-93.
ABSTRACT
| FULL TEXT
Perinatal Correlates of Cerebral Palsy and Other Neurologic Impairment Among Very Low Birth Weight Children
Wilson-Costello et al.
Pediatrics 1998;102:315-322.
ABSTRACT
| FULL TEXT
Trends in Mortality and Cerebral Palsy in a Geographically Based Cohort of Very Low Birth Weight Neonates Born Between 1982 to 1994
O'Shea et al.
Pediatrics 1998;101:642-647.
ABSTRACT
| FULL TEXT
Neurologic Outcome of Prematurity
Volpe
Arch Neurol 1998;55:297-300.
ABSTRACT
| FULL TEXT
More on Prenatal Magnesium Sulfate and Risk of Cerebral Palsy
Nelson and Grether
JAMA 1997;278:1493-1493.
ABSTRACT
Magnesium Sulfate in Labor and Risk of Neonatal Brain Lesions and Cerebral Palsy in Low Birth Weight Infants
Paneth et al.
Pediatrics 1997;99:e1-e1.
ABSTRACT
| FULL TEXT
Prenatal Magnesium Sulfate Exposure and Risk of Cerebral Palsy
Allred et al.
JAMA 1997;277:1033-1033.
ABSTRACT
Magnesium Seems to Prevent CP and MR in Low-Birth-Weight Children
JWatch Women's Health 1997;1997:16-16.
FULL TEXT
Magnesium Sulfate and Risk of Cerebral Palsy in Very Low-Birth-Weight Infants
Nelson
JAMA 1996;276:1843-1844.
ABSTRACT
|
